Search Results

Calyxt, Inc. announced the results of the special meeting of its stockholders held on May 18, 2023.

Calyxt, Inc. announced that it has completed the previously announced reverse stock split of Calyxt’s common stock, par value $0.0001 per share, at a ratio of 1-for-10.

Calyxt, Inc. (Nasdaq: CLXT) (“Calyxt” or the “Company”) today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company’s shareholders at the annual meeting of shareholders on June 1, 2022.

Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt”), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the “Merger Agreement”), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023.

Calyxt, Inc., a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission by Calyxt on February 14, 2023, and amended on April 14, 2023, has been declared effective by the SEC.

Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt”), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its fourth quarter ended December 31, 2022.

Cellectis S.A. announced today that Calyxt, Inc. today announced operating and financial results for its fourth quarter ended December 31, 2022.

Calyxt, Inc., a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, announced that Calyxt has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on February 14, 2023.